Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid by R. Marignier et al.
RESEARCH Open Access
Neuromyelitis optica study model based on
chronic infusion of autoantibodies in rat
cerebrospinal fluid
R. Marignier1,2,3*, A. Ruiz1,2, S. Cavagna1,2, A. Nicole1, C. Watrin1,2, M. Touret1,2, S. Parrot1,2, G. Malleret1,2, C. Peyron1,2,
C. Benetollo1,2, N. Auvergnon1,2, S. Vukusic1,2,3 and P. Giraudon1,2
Abstract
Background: Devic’s neuromyelitis optica (NMO) is an autoimmune astrocytopathy, associated with central nervous
system inflammation, demyelination, and neuronal injury. Several studies confirmed that autoantibodies directed against
aquaporin-4 (AQP4-IgG) are relevant in the pathogenesis of NMO, mainly through complement-dependent toxicity
leading to astrocyte death. However, the effect of the autoantibody per se and the exact role of intrathecal AQP4-IgG
are still controversial.
Methods: To explore the intrinsic effect of intrathecal AQP4-IgG, independent from additional inflammatory effector
mechanisms, and to evaluate its clinical impact, we developed a new animal model, based on a prolonged infusion of
purified immunoglobulins from NMO patient (IgGAQP4+, NMO-rat) and healthy individual as control (Control-rat) in the
cerebrospinal fluid (CSF) of live rats.
Results: We showed that CSF infusion of purified immunoglobulins led to diffusion in the brain, spinal cord, and optic
nerves, the targeted structures in NMO. This was associated with astrocyte alteration in NMO-rats characterized by loss
of aquaporin-4 expression in the spinal cord and the optic nerves compared to the Control-rats (p = 0.001 and p = 0.02,
respectively).
In addition, glutamate uptake tested on vigil rats was dramatically reduced in NMO-rats (p = 0.001) suggesting
that astrocytopathy occurred in response to AQP4-IgG diffusion. In parallel, myelin was altered, as shown by the
decrease of myelin basic protein staining by up to 46 and 22 % in the gray and white matter of the NMO-rats
spinal cord, respectively (p = 0.03). Loss of neurofilament positive axons in NMO-rats (p = 0.003) revealed alteration
of axonal integrity. Then, we investigated the clinical consequences of such alterations on the motor behavior of
the NMO-rats. In a rotarod test, NMO-rats performance was lower compared to the controls (p = 0.0182). AQP4
expression, and myelin and axonal integrity were preserved in AQP4-IgG-depleted condition. We did not find a
major immune cell infiltration and microglial activation nor complement deposition in the central nervous
system, in our model.
Conclusions: We establish a link between motor-deficit, NMO-like lesions and astrocytopathy mediated by
intrathecal AQP4-IgG. Our study validates the concept of the intrinsic effect of autoantibody against surface
antigens and offers a model for testing antibody and astrocyte-targeted therapies in NMO.
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Background
Devic’s neuromyelitis optica (NMO) is now considered
a primary astrocyte disease associated with central nervous
system (CNS) inflammation, demyelination, and neuronal
injury [1–5]. Aquaporin-4 autoantibody (AQP4-IgG) plays
a major role in this astrocytopathy. Several clinical, im-
munological, and pathological studies have demonstrated
that AQP4-IgG is pathogenic through complement-
dependent astrocyte toxicity [6–9].
However, autoantibodies against membrane antigen can
also act directly as receptor agonists/antagonists or modu-
late antigen density and trigger cell dysfunction, prior or in
addition to complement activation or secondary inflamma-
tory cell-mediated response [10]. These mechanisms prob-
ably take part, to some extent, in NMO. In fact, some
patients experience fully reversible clinical symptoms and
MRI abnormalities, suggesting a transient modulatory
phenomenon rather than a destructive one [11]. Modula-
tion of AQP4 membrane expression has also been demon-
strated in several study models and associated with
increase blood-brain barrier permeability, water balance
disruption, and glutamate excitotoxicity [12–14]. Recent
detailed study of NMO pathology showed different lesion
types, some associated to complement and immune
cells infiltration but others with selective astrocyte loss
in the absence of complement activation and granulo-
cyte infiltration [15].
These data strongly support the idea of an intrinsic
modulatory effect of AQP4-IgG in NMO. Studies pro-
viding evidence for a direct pathogenic role of AQP4-
IgG were mainly performed in co-existing inflammatory
conditions [16–20]. Recently, Geis et al. investigated the
effect of the autoantibody itself by performing repeated
local injection of high dose of purified immunoglobulins
from AQP4-IgG-positive patients in the spinal cord of
rats. They found a reversible downregulation of AQP4
with preserved astrocyte, axon, and myelin in contact to
inflammatory reaction at the site of injection, associated
with transient clinical changes and correlated it with
“penumbra-like” lesions recently reported in NMO [21].
To explore more widely the intrinsic immunopatho-
genic effect of AQP4-IgG and its functional and mor-
phological consequence not only on astrocyte but also
on myelin and axons and to evaluate its clinical impact,
we have developed a new animal model of NMO based
on a chronic infusion of “physiological dose” of purified
immunoglobulins (IgG) from NMO patient and healthy
individual, into the cerebrospinal fluid (CSF) of live rats.
Here, we show that chronic in vivo CSF infusion of
purified AQP4-IgG alone leads to diffusion of all CNS
structures and induces NMO-like lesions mainly in
the optic nerve and the spinal cord. These histopatho-
logical changes are associated with motor behavioral
changes, probably via astrocytopathy and glutamate
homeostasis disturbance, and happen in the absence
of the major complement deposition or immune cell
infiltration.
Methods
Patients, IgG purification of samples for animal
experiments
Sera and/or plasmapheresis were obtained from three pa-
tients with NMO spectrum disorder [22] selected from the
French NMO cohort NOMADMUS and stored at Neuro-
BioTec (Biological Resource Centre of the Hospices Civils
de Lyon). All sera were tested positive for AQP4-IgG [23].
We also used control sera collected from three healthy
blood donors at Etablissement Français du Sang. IgG were
purified from the sera and plasmapheresis on Protein-A
Sepharose 4 Fast FlowTM beads (P9424 Sigma-Aldrich ®),
eluted with glycine 0.1 M buffer pH 2.8 and then neutral-
ized in Tris 1.5 M pH 8.8. The samples were concentrated
to obtain an IgG concentration of 1.5–2 mg/mL. We
termed IgGAQP4+1–3 as the total IgG isolated from the
three AQP4-IgG-seropositive sera and IgGControl1–3 as
the total IgG isolated from the three sera of the healthy
donors. IgGAQP4+1–3 displayed a strong positive anti-
AQP4 binding pattern on HEK-AQP4 cells using flow cy-
tometry. Prior to their use for brain infusion, purified IgG
were tested for immunoreactivity on rat CNS tissue. They
stained astrocytes and co-localized it with glial fibrillary
acidic protein (GFAP) and AQP4 in the rat brain, spinal
cord, and optic nerve (Additional file 1: Figure S1A).
IgGControl showed no specific staining on astrocyte (not
shown). The pathogenicity of IgGAQP4+ was tested on cul-
tured astrocytes. As shown by Western blot analysis,
IgGAQP4+ decreased AQP4 expression in the total astro-
cyte lysate (Additional file 1: Figure S1B) (51 ± 21 decrease
versus 1.5 ± 3 % decrease with IgGControl, p = 0.008) and
membrane preparation (Additional file 1: Figure S1C) fol-
lowing 24-h exposure.
AQP4-IgG depletion
Human embryonic kidney-293 cells stably transfected
with human AQP4-M23 plasmid (HEK-AQP4 cells engi-
neered by CreaCell®, Grenoble France) were seeded in
six-well plate at a density of 1 × 06 cells. IgGAQP4+ was
added in each well to live HEK-AQP4 cells for 20 min
per well at 37 °C, CO2 atmosphere and gentle rotation.
Contact with cells was performed six times. After cell
contact, depleted IgGAQP4+ was removed, centrifuged for
15 min at 12.000 rpm, then tested for AQP4 antibody
titer by flow cytometry, as already described [24]. Ad-
sorption of IgGAQP4+ on HEK-AQP4 cells decreased
AQP4 antibody level by almost 40 % (Fig. 8e). Adsorbed
IgGAQP4+ were termed IgGAQP4+dep.
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Animals, surgery and intraventricular infusion
For the purpose of this work, a total of 65 Oncins
France Strain A (OFA) rats were included. Animal ex-
periments were carried out in strict accordance with
the European Directive 2010/63/UE and follows the
Animal Research: Reporting of In Vivo Experiments
(ARRIVE) guidelines on the protection of animals used
for scientific purposes. Adult male OFA rats at 280 g
(Janvier; Le Genest Saint Isle, France) were acclimated to
the new environment for 7 days prior to the start of the
experiment. The local Lyon 1 University Animal Care
Committee has approved all the experimental procedures
on animals (BH2012-80 project). A total of 33 rats re-
ceived IgGAQP4+ (termed NMO-rats), 15 rats received
IgGControl (termed Control-rats), 15 rats received NaCl
(termed Saline-rats). One experimental group was dedi-
cated to immunodetection analyses (immunohistochemis-
try (IHC), Western blot) (eight NMO-rats, eight Control-
rats, one Saline-rat). Two rats of each IgG group were
sacrificed on day 14 (D14) following the beginning of
perfusion, the others being sacrificed on D7. The sec-
ond experimental group was dedicated to in vivo ana-
lysis of glutamate uptake, performed on D7 (four
NMO-rats; four Control-rats). The third experimental
group was dedicated to behavioral study performed on
D3, D7, D10, D14, and D21 (ten Saline-rats, ten NMO-
rats). A fourth group was dedicated to transmission
electron microscopy analyses (five NMO-rats, one
Control-rat, two Saline-rats). In addition, several con-
trol experiments included (i) infusion of IgG following
AQP4-IgG depletion (three NMO-ratAQP4+dep); (ii) 2-
day treatment with cobra venom (two rats); (iii) being
together with five NMO-rats. All were examined
using IHC.
For surgery, the rats were continuously anesthetized
with volatile isoflurane (Aerrane, Baxter SAS, France) and
mounted conventionally in a stereotaxic frame (David
Kopf, Epinay-sur-Seine, France). The scalp was shaved and
incised, and the skull was cleaned and dried. Then, 400 μg
of purified IgG (IgGAQP4+, IgGControl, IgGAQP4+dep; 200 μL
at 2 μg/μL) or 200 μL NaCl were infused into the CSF
during 7 days at a rate of 1 μL/h, using a sterile mini-
osmotic pump implanted subcutaneously between the rat
scapulae and previously connected to a brain infusion kit
(osmotic pump ALZET, Charles Rivers, France). The can-
nula of the brain infusion kit was lowered into the right
lateral ventricle using stereotaxic coordinates (anteropos-
terior (AP) −0.7 mm; mediolateral (ML) −1.7 mm from
Bregma; depth, 5 mm from the skull surface) and strongly
fixed to the skull with superglue. After surgery, the rats
were maintained on a 12-h light/dark cycle and housed in
transparent individual cages with food and water ad libi-
tum for up to 21 days, depending on the conducted
experiments.
Tissue preparation and harvesting,
immunohistochemistry, and immunoblot
At the end of brain infusion (D7) and on D14 and D21,
the rats were anesthetized and received intracardiac per-
fusion with 100 mL phosphate-buffered saline (PBS;
0.1 M pH 7.4) to remove blood cells. The rats were then
killed with a lethal dose of pentobarbital. Following re-
moval from the skull and laminectomy, the brain, spinal
cord, and the optic nerves were frozen in isopentane at
−30 °C and stored at −80 °C. Just before IHC, neural tis-
sue was embedded in Tissue-Tek OCT® compound for
optimal cutting and prepared as 8–10-μm sections on a
cryomicrotome. These slices were used for immunode-
tection. Contact with primary antibody (4 °C, overnight)
was followed by three washes and 5-h contact at room
temperature with Alexa-488-, Alexa-555-, or Alexa-647-
labeled anti-mouse, anti-rabbit, and anti-human IgG
antibody (Molecular Probes A11013, USA).
Following IHC, the tissue sections were viewed and
digitized with an Axio Imager Z1 apotome technology
(Zeiss, Oberkochen, Germany) by an examiner blinded
to treatment allocation with the appropriate filter set-
tings using AxioVision Rel 4.8 software. Analyses were
performed with ImageJ 1.4 software (Wayne Rasband
NIH, USA, public domain). For IHC signal intensity
analyses, all immunostaining were digitized with the
identical microscope and software settings. For quanti-
fication, a standardized area was analyzed in different
CNS structures of interest: the spinal cord gray and
white matter, the optic nerve, the corpus callosum, and
the periventricular areas. Means of intensity values of
each animal were then taken for further analyses. For
axon analyses, axons in the immunostained spinal cord
slices (neurofilament (NF)-M detection) were digitized,
organized according their surface (10 to 140 μm2) and
counted using ImageJ software.
For immunoblot (Western blot), tissue punches from
the periventricular areas, corpus callosum, and spinal cord
were dissociated using ultrasound fragmentation in
homogenization buffer containing Tris 20 mM, EDTA
1 mM, EGTA 1 mM, sucrose 10 % pH 7.4, protease in-
hibitor (Complete EDTA free, Roche Diagnostics GmbH
69298 Mannheim, Germany) and phosphatases inhibitors
(sodium fluoride 10 mM, sodium pyrophosphate
2 mM, sodium beta-glycerophosphate 2 mM, sodium
orthovanadate 2 mM). The samples were screened for
protein content (Qubit® Protein Assay Kits Q33212
Molecular Probes®) then examined for protein expres-
sion using Western blotting as described [25]. Briefly,
proteins were separated on SDS-PAGE gels (1–5 μg
per lane, 10 % Criterion™ XT Bis-Tris Gel and 4–12 %
Criterion™ XT Bis-Tris Gel, © Bio-Rad Laboratories Inc
Hercules CA 94547), transferred on nitrocellulose (Pro-
tran® Nitrocellulose Hybridization Transfer Membrane
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0.45 μm Whatman®), immunodetected (antibody diluted
in Tris buffer saline (TBS) containing 1 % non-fat dry milk
and 0.1 % Tween-20) using primary antibody (4 °C over-
night) and anti-IgG antibody (1-h room temperature), and
revealed using chemiluminescence (Immobilon Western
Chemiluminescent HRP Substrate WBKLS0500 Millipore
Merck KGaA Darmstadt Germany; Amersham Hyper-
film™ ECL GE Healthcare UK Ltd Buckinghamshire UK).
Band density was evaluated using ImageJ software.
Transmission electron microscopy
Transmission electron microscopy (TEM) was performed
at the CIQLE facilities—Centre d'Imagerie Quantitative
Lyon-Est (http://sfrsantelyonest.univ-lyon1.fr/plateau31-
ciqle.html). The rats were perfused with a washing solu-
tion containing cacodylate and CaCl2, then with a fixing
solution 2 % paraformaldehyde, 2 % glutaraldehyde, caco-
dylate, and CaCl2. The optic nerve and fragment of
1 mm3 of the spinal cord were postfixed in the fixation so-
lution overnight at 4 °C, then dehydrated in alcohol con-
taining 0.1 % tannic acid and embedded in Epon resin.
Ultrathin sections (70-nm thick) were cut with a Reichert
Ultracut E (Leica) ultra-microtome, mounted on 200
mesh copper grids coated with 1:1000 poly-lysine and
contrasted with uranyl acetate and lead citrate. The sec-
tions were observed in a Jeol 1400JEM (Tokyo, Japan)
transmission electron microscope operating at 80 kV
equipped with an Orius 600 camera and Digital Micro-
graph. Tissue examination was performed on five
NMO-rats, one Control-rat, and two Saline-rats. In
each treatment condition, ≈20 areas in the optic nerve
and spinal cord were examined.
Astrocyte primary culture and immunocytochemistry
Primary glial cultures were obtained by mechanical dis-
ruption of microdissected cortices from 1-day-old rat
pups, as previously described [24]. Dissociated cells were
diluted to a density of 2.105 cells/mL in Dulbecco’s modi-
fied Eagle medium (DMEM) minimal essential Glutamax
medium (Gibco, Life Technologies, France) containing
4.5 g/L glucose, supplemented with 20 % heat-inactivated
fetal calf serum and gentamycin (1 μg/mL). The cells were
seeded in six-well plates and LabTek slides pre-coated
with poly-L-lysine (3 μg/mL in 0.1 M borate buffer, pH
8.4) and incubated at 37 °C in a moist 5 % CO2, 95 % air
atmosphere. The medium was changed every 3 days after
plating (10 % fetal calf serum) and treated with cytosine
arabinoside (AraC, 25 nM, Sigma-Aldrich) to eliminate
microglia and oligodendrocyte and to obtain pure cul-
tured astrocytes. Immunocytochemistry was performed
on acetone-fixed cells (10 min, −20 °C) or paraformal-
dehyde (4 %, 15 min) (primary antibody 45 min 37 °C,
fluorochrome-labeled anti-IgG antibody 30 min room
temperature). The culture was treated with IgGAQP4+
and IgGControl (75 μg/mL) for 24 h before astrocyte
protein analysis. Subcellular fractioning of astrocyte
was performed using the ProteoExtract® subcellular
proteome extraction kit (Merck Millipore) and proteins
analyzed using Western blot.
Immunodetection
The following antibodies were used for immunodetection
on the tissue samples and cell culture and lysates. The pri-
mary antibodies to AQP4 are as follows: rabbit AB2218,
Merck© KGaA, Darmstadt, Germany; beta-actin, MoAb
A1978, Sigma-Aldrich®, St. Louis, MO 63103, USA; GFAP:
rabbit Z0334, Dako Denmark A/S; GLT1-EAAT2: Mouse
anti-EAAT2, ab77039, Abcam®; Iba-1: rabbit 019-19741,
Wako Chemicals USA, Inc; MBP: MoAb MCA70, AbD-
Serotec©, Bio-Rad Laboratories, Inc; Neurofilament Heavy
(NF-H): rabbit AHP2259GA, AbDSerotec© Bio-Rad La-
boratories, Inc; Neurofilament Medium (NF-M): MoAb
ab7794; phospho-Neurofilament: SMI34, MoAb ab24571
Abcam® Cambridge, UK; human IgG: Biotin-SP-conjugated
affinityPure donkey anti-human IgG 709-065-149 Jackson
ImmunoResearch; CD45 pan lymphocyte: mouse clone
Ox-1, BD Pharmingen™; CD45RA: mouse clone OX33, BD
Pharmingen™; CD8: mouse antibody 554854 BD Pharmin-
gen; and olig2: rabbit antibody AB9610, Millipore. The
secondary antibodies are: Peroxidase-AffiniPure F(ab’)2
fragment donkey anti-mouse IgG(H+L) 715-036-151;
Peroxidase-affiniPure F(ab’)2 fragment donkey anti-
rabbit IgG(H+L) 711-036-152 Jackson ImmunoResearch
Laboratories, Inc. west Grove PA; Alexa Fluor®488 goat
anti-mouse IgG A11029; Alexa Fluor®555 goat anti-mouse
IgG A21424; Alexa Fluor®488 goat anti-rabbit IgG A11034
; and Alexa Fluor®455 goat anti-rabbit IgG A21429 from
Molecular Probes Inc.
In vivo microdialysis and measurement of glutamate
uptake
A method previously described by our group [26] was
used to assess in vivo glutamate uptake in the rat hippo-
campus. Concentric microdialysis probes were thus con-
structed and, before implantation, were perfused at a
rate of 1 μL/min with artificial cerebrospinal fluid (aCSF)
(149 mM NaCl, 2.80 mM KCl, 1.2 mM MgCl2, 1.2 mM
CaCl2, 2.78 mM phosphate buffer, pH 7.4). A probe was
implanted into the guide cannula of a freely moving rat
placed in a plexiglass cylinder, the inlet and outlet of the
probe being connected to a liquid swivel (Instech Solo-
mon, USA). The rate of infusion was 2 μL/min. For each
dialysis experiments, at least 3 h was allowed to elapse
after microdialysis probe implantation before collecting
basal samples. At the end of the experiment, the rats
were killed with a lethal dose of pentobarbital, and the
placement of the cannula was verified on the removed
brain [27].
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Uptake experiments were performed by switching the
microdialysis probe perfusion fluid for 10 min to aCSF
containing 250 μM 3H-glutamate (GLU) (15 Ci/mMol)
and 120 μM 14C-mannitol (MAN) (60 mCi/mMol) (Per-
kinElmer Life and Analytical Sciences, USA), samples of
microdialysis probe effluent being collected every 2 min
for dual-label scintillation counting. The relative GLU
uptake was determined using the “recovery” versus “time”
curves for 3H-GLU and 14C-MAN used as the reference,
as cells do not take it up. The recovery is the counts exit-
ing the probe/input counts ratio (Eqs. 1 and 2). The cellu-
lar extraction fraction for Glu corrected for mannitol is
calculated as in Eq. 3.
RMAN ¼ MAN outlet=MAN inlet ð1Þ
RGLU ¼ GLU outlet=GLU inlet ð2Þ
EL‐GLU ¼ RMAN−RGLU=RMAN ð3Þ
Motor behavior analyses
The accelerating rotarod apparatus [28] was used to meas-
ure motor coordination. Prior to surgery, the animals were
pre-trained for three consecutive days, receiving two trials
per day with a 4-h inter-trial interval until they reached
the criteria 2-min stay on the rotating rod. The animals
not reaching the criteria were excluded from the behav-
ioral experiments. There was no weight loss for rats along
the experimentation (Additional file 2: Figure S2A). The
NMO-rats (n = 10) and Saline-rats (n = 10) were thus pre-
trained to balance on the accelerating rod prior to surgery
and then tested at D3, D7, D10, D14, D17, and D21 post-
surgery. The latency to fall during the observation period
was recorded and normalized to D0 (prior to surgery) per-
formance. Prior to the rotarod test, the rats were exam-
ined for their ability to grip a suspension bar. There was
no clear difference between the two groups. An observer
blinded to the group assignment scored the amount of
time the animal spent on the rotarod. In order to assess
the natural walking pattern of each animal, motor behav-
ior was also analyzed in a non-forced complete stepping
sequence task on D0, D7, D14, and D21. A walking appar-
atus was thus adapted from Metz and Whishaw [29]. In
this task, the rats were invited to walk in a corridor to
mark their footprints. This corridor consisted of a flat
floor (1.0 mL × 9.5 cm l × 19.0 cm) closed by two wooded
sidewalls. At one end of the corridor, the rat could be
placed in a resting box where an ink stamp placed on the
floor allowed the labeling of the rat’s fingers and paws.
The marks left by the rat’s footprints as it moved along
the corridor were collected on paper. A manual scoring
was determined for the analysis of footprints. Distance be-
tween anterior legs, distance between posterior legs, width
between anterior legs, width between posterior legs, and
difference in finger gauge of anterior legs were thus evalu-
ated (Additional file 3: Figure S3B). Using these footprints,
the experimenter was thus allowed to compute the trajec-
tory of the rat and to assess if this trajectory deviated from
the linear trajectory initially taken by the rat when enter-
ing the corridor at D0, D7, D14, and D21. Figure 7b shows
the percentage of shift from D0 deviation. Using this
analysis of the left forepaw prints, deviation from the
line trajectory taken by the rat once it entered the cor-
ridor was computed and scored on D0, D7, D14, and
D21, and results were expressed as a percentage of shifts
to D0 performance (deviation observed prior to surgery).
An observer masked to group assignment analyzed the
natural walking of each animal.
Statistical analyses
Investigators blinded for treatment condition performed
analyses of immunodetection, Western blot and electron
microscopy. Following quantification of fluorescence in-
tensity (immunodetection) and Western blot signal, data
are presented as mean ± SD. Considering the non-normal
distribution, we used the non-parametric Mann-Whitney
test to compare two groups and one-way ANOVA to com-
pare more than two groups. The levels of significance were
indicated as follow: *p < 0.05, **p < 0.01, and *** p < 0.001.
For glutamate uptake measurement, we compared differ-
ences in uptake between the mean ± SEM for the NMO-
rats (n = 4) and the Control-rats (n = 4) using the unpaired
Student’s t test and a level of significance of p < 0.05.
Computation was performed using Prism 5.0 GraphPa-
d.Inc software. For behavioral analysis, we used re-
peated measures ANOVAs to assess the variation of
performance over days.
Results
IgGAQP4+ infused in the rat CSF diffused in the CNS and
induced astrocytopathy
To validate our model of chronic infusion of autoantibody
in rat CSF, we controlled the presence of human IgG in
neural tissues of eight rats infused with IgGAQP4+ (NMO-
rats) and eight rats infused with IgGControl (Control-rats)
on D7 and D14. Human IgG was detected by IHC in dif-
ferent brain structures and in the optic nerve and spinal
cord of the NMO-rats (Fig. 1a) and the Control-rats.
Western blot performed on neural tissue from the NMO-
rats and the Control-rats showed accumulation, at various
levels, of human IgG (H and L chains) in the infused CNS
(Fig. 1b). Altogether, we detected the diffusion of CSF-
infused human IgG in the rat CNS.
We further searched for astrocyte alteration, focusing
our analysis on AQP4 expression in the spinal cord and
optic nerve of the NMO-rats (n = 8) and the Control-
rats (n = 8) examined at D7 and D14. IHC showed a de-
creased AQP4 expression in the spinal cord of the
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NMO-rats compared to the Control-rats (Fig. 2a), a de-
crease confirmed by evaluation of the AQP4 level (fluor-
escent intensity), in the white and gray matter (Fig. 2b)
(p = 0.001). Western blot (Wb) performed on all rats
(Fig. 2b) confirmed the AQP4 decrease in the NMO-rats
(p = 0.02). AQP4 decrease was not due to astrocyte loss
as IHC and Western blot rather detected an increased
GFAP expression (Fig. 2a, b (p = 0.02), respectively), sug-
gestive of reactive cells. In the optic nerve, IHC per-
formed and quantified on all rats, detected AQP4 loss
in the NMO-rats compared to the Control-rats (Fig. 2c,
p = 0.02). Globally, AQP4 loss in the NMO-rats was not
restricted to perivascular area and occurred without
marked astrocyte loss. Decrease of AQP4 expression
also occurred in other myelinated CNS structures of
the NMO-rats, notably tractus optica and corpus callo-
sum (not shown).
Astrocyte integrity was examined at the ultrastructural
level (transmission electron microscopy) in the spinal cord
and optic nerve at D7 (Fig. 3). In the optic nerve, the more
striking modification is the loss of astrocytic processes
delimiting axons bundles in the NMO-rats compared to
the Control-rats (Fig. 3a, b). The presence of damaged
mitochondria in the cytoplasm and processes of astrocytes
together with tissue disorganization complemented this
observation and suggested cell dysfunction (Fig. 3b). Dam-
aged mitochondria were also observed in the axons of the
optic nerve (Fig. 3b). In the spinal cord (Fig. 3c, d), dam-
aged mitochondria are present in some astrocytes and
axons within the gray matter (GM) and white matter
(WM). Functional integrity of astrocyte was then tested by
microdialysis on vigil IgG-infused rats, a method that
reveal the ability of astrocytes to uptake glutamate. The
microdialysis probe was implanted in the hippocampus,
a brain structure rich in glutamate and where infused
human IgG accumulated (Fig. 4a). A mixed solution of
3H-glutamate and 14C-mannitol (mannitol used as a
non-uptaken molecular control) was infused in NMO-
rats (n = 4) and Control-rats (n = 4). At D7, analysis of













































Fig. 1 Human IgG chronically infused in the rat brain ventricle widely diffused in the neural tissues. a Detection of human IgG in the rat brain,
spinal cord, and optic nerve using immunohistochemistry (rat infused with IgGAQP4+2, D7 as and example). Scale bar 10 μm. Hip hippocampus, Cx
cortex, CC corpus callosum, MB midbrain, ME median eminence, 3V third ventricle. b Detection of human immunoglobulin IgH and IgL chains
(black arrows) accumulated in neural tissues of NMO-rats (received IgG-NMO) and Control-rats (received control IgG) ((asterisk) D7 and D14) using
Western blot (actin as protein deposition control, same blot. Control: neural tissue from rat receiving saline buffer)
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showed that glutamate uptake was dramatically reduced
in the NMO-rats compared to the Control-rats (p = 0.001)
(Fig. 4b). To understand the basis of such a functional al-
teration, we analyzed the expression of the glutamate
transporters glutamate transporter type 1 (GLT1) and glu-
tamate aspartate transporter (GLAST) in the implanted
brain area, using Western blot. Compared to the Control-
rats, a shift in the molecular weight (≈3 kDa) of GLT1 and
GLAST was detected in the NMO-rats, suggesting protein
modification (Fig. 4c). Analyzing subcellular distribution
of GLT1 in cultured astrocytes after 24-h contact with
IgGAQP4+, we observed that GLT1 level was not modified
in the total cell lysate but was deeply reduced in the mem-
brane cell fraction (Fig. 4d). Treatment with IgGControl did
not modify GLT1 expression. Thus, protein modification
and decreased membrane expression of glutamate trans-
porters induced by treatment with IgGAQP4+ could sup-
port the decreased glutamate uptake in the NMO-rats.
IgGAQP4+-induced astrocytopathy is associated with
myelin alteration, axonal damage, and motor impairment
Dysfunction of astrocyte induced by AQP4-IgG could
have a serious consequence on myelin and axon. We first
investigated myelin integrity in the spinal cord and optic
nerve of the IgG-infused rats (D7, D14). Immunodetection
of myelin basic protein (MBP) showed a diffuse myelin al-
teration in the GM and WM of the spinal cord of the
NMO-rats examined at D7 (Fig. 5a). Myelin alteration also
occurred in the corpus callosum of the NMO-rats (Fig. 5a)
but was not obvious in the optic nerve (not shown). Evalu-
ation of MBP staining intensity in the rat spinal cord
(Fig. 5b, p = 0.03) confirmed its decrease in the NMO-rats
(n = 4) compared to the Control-rats (n = 5), with a
marked alteration in the GM (mean decrease, 30 ± 9.9 %
in the GM versus 17.4 ± 7 % in the WM). Myelin alter-
ation was confirmed at D21 by proteolipid protein
(PLP) labeling (mean decrease of fluorescence intensity,
39.5 ± 0.1 %) and associated the loss of olig2-positive
oligodendrocytes in the NMO-rats compared to the
Control-rats (39.6 ± 7.6 versus 66.8 ± 16 positive cells
per field, respectively, p < 0000,1). Oligodendrocyte loss
was not detected at D7.
We further examined axonal integrity using neurofila-
ment M subunit (NF-M) as axonal marker (Fig. 6). In
the WM spinal cord, the number of axons, detected as






















































































Fig. 2 Chronic infusion of IgGAQP4+ decreased AQP4 expression in the rat spinal cord and optic nerve. a Example of AQP4 loss with preserved
GFAP-positive astrocytes in the spinal cord of the NMO-rat compared to the Control-rat (D7, rat infused with IgGAQP4+1,2 and IgGControl1,2 as an
example) IHC immunohistochemistry. Scale bars = 20 μm. b Confirmation of AQP4 loss using evaluation of AQP4 expression in the white and gray
matter of the NMO-rat spinal cord (n = 5) compared to the Control-rat (n = 4), by IHC (fluorescence intensity) and Western blot (Wb, relative to
actin). In parallel, GFAP expression is enhanced (Wb). c Loss of AQP4 expression in the optic nerve of the NMO-rat as shown by IHC and evaluation of
fluorescence intensity (*p < 0.05; ***p < 0.001, ANOVA)
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rats (n = 6) compared to the Control-rats (n = 6) (Fig. 6a).
Classification (10–20 to 100–140 μm2) and quantifica-
tion (mean by field) of NF-M spots confirmed the loss of
axons in the NMO-rats (Fig. 6b, p = 0.003), notably the
loss of 60–140 μm2 axons. In the GM spinal cord of the
NMO-rats, axons appeared fragmented and reduced in
thickness (Fig. 6a). Axonal loss was associated with mye-
lin disorganization, as shown in the WM by MBP and
NF-M co-immunolabeling (Fig. 6c). Western blot ana-
lysis of the extensively phosphorylated form of NF-H
(pNF-H) in the spinal cord of all rats showed an in-
creased expression of this biomarker of axonal injury
[30] in the NMO-rats (Fig. 6d, p = 0.04). Axonal alter-
ation was also detected in the optic nerve of the NMO-
rats. NF-M-positive axons had reduced thickness and
became fragmented (Fig. 6e). Analysis at ultrastructural
level (transmission electron microscopy) confirmed the
axonal loss in the optic nerve (178.2 ± 15 axons per field
(n = 11) in the Control-rats versus 118.2 ± 7 in the
NMO-rats, p = 0.001). Assuming that myelin and axonal
alteration may have consequence on motor behavior, we
used the rotarod test to investigate motor coordination
and a stepping sequence task to evaluate the walking
pattern of the NMO-rats (n = 10) compared to the con-
trols (n = 10) (examination at D3, D7, D10, D14, and
D21). At baseline, motor characteristics did not differ in
the NMO-rats as compared to the Saline-rats for both
rotarod test (67 ± 9 s, n = 10 versus 47 ± 11 s, n = 11, un-
paired t test, p = 0.1709) and walking deviation experi-
ments (0.4 ± 0.1 cm, n = 10 versus 0.5 ± 0.1 cm, n = 11,
unpaired t test, p = 0.2694). In the rotarod procedure,
the NMO-rats were greatly impaired (Fig. 7a). ANOVAs
revealed that the NMO-rats latency to fall was consist-
























































Fig. 3 Astrocyte and axonal alteration detected at the ultrastructural level in the optic nerve and spinal cord of NMO-rats. a, b Transmission
electron microscopy on the rat optic nerve (D7, rat infused with IgGAQP4+3 as an example). a Loss of astrocytic processes in the NMO-rat compared to
the Control-rat, as shown in the corresponding drawings of astrocytic processes (dotted line). A astrocyte nucleus. b Axon bundle disorganization and
altered mitochondria in astrocytic processes in NMO-rat (red arrow). Altered mitochondria were also present in axon (Ax). c, d Transmission electron
microscopy on the rat spinal cord, in the gray (GM) and white matter (WM): altered mitochondria in NMO-rat (red arrows) compared to the Control-rat
c in astrocytes and d in axon (Ax)
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Fig. 4 Functional astrocyte alteration in NMO-rat. a Rats were implanted (white arrow) with a microdialysis probe in the hippocampus (hip), where
infused human IgG accumulated (lower figure) (D7). b Decreased glutamate uptake in NMO-rats detected using in vivo uptake of exogenous radioactive
glutamate (3H-GLU) and mannitol (14C-MAN, used as the reference molecule not taken up by cells) in the brain of the vigil NMO-rats (IgGAQP4+2, n= 4)
and the Control-rats (IgGControl2, n= 4) (10-min infusion and collection of microdialysis probe effluent every 2 min for dual-label counting). The relative
glutamate uptake was determined by Eq. 3 (EL-GLU = RMAN − RGLU/RMAN) using the “recapture” curves for
3H-GLU and 14C-MAN and expressed as the
mean ± SEM. c Change in the apparent molecular weight of the glutamate transporters GLT1 and GLAST detected by Western blot in the NMO-rats
compared to the Control-rats (periventricular area, actin as control of protein deposition). d Cell fractioning of cultured astrocytes treated with IgGAQP4+
(24 h): loss of GLT1 expression in the membrane fraction although the total cell lysate remained unchanged (Western blot). No similar effect with
IgGControl treatment
a b
Fig. 5 Myelin alteration in the spinal cord and corpus callosum of NMO-rat. a Myelin alteration detected by myelin basic protein (MBP) immunostaining
in the spinal cord (gray (GM) and white matter (WM)) and corpus callosum (CC) of the NMO-rats compared to the Control-rat (D7, rats infused with
IgGAQP4+1,2 and IgGControl2 as example). b MBP decreased expression in the spinal cord and corpus callosum of the NMO-rats (n = 4) compared to the
Control-rats (n = 5), as shown by evaluation of fluorescence intensity (p < 0.05, ANOVA). Scale bars= 20 μm
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effect: F(1,18) = 6742; p = 0.0182). In addition, a post hoc
analysis revealed that the NMO-rat latency to fall was
significantly lower than their 100 % baseline (perform-
ance on D0 prior to surgery—p < 0.0001). This was not
the case for the Saline-rats (p = 0.8244). The NMO-rats
performance decreased over days to reach a latency of
50 ± 16 s on D21. The rats were also tested in a non-
forced complete stepping sequence task (Fig. 7b). A sig-
nificant difference was observed at D21 between the
NMO-rats and the Saline-rats, with the NMO-rats
showing a greater impairment in their walking pattern
(deviation from line trajectory) as compared to the Saline-
rats (F(1,18) = 5.962; p = 0.0252). In parallel, alteration of
AQP4, GLT1, and pNF-H expression was detected by
Western blot in the spinal cord of the NMO-rats (D21)
compared to the Saline-rats (Fig. 7c).
Rat NMO-like lesions are dependent of IgGAQP4+
To ascertain that the lesions observed in the NMO-rats
were directly due to the presence of AQP4-IgG, we in-
fused three rats with IgGAQP4+ previously depleted in





Fig. 6 Axonal damage and loss in the spinal cord and optic nerve of the NMO-rat. a Axon injury detected in the NMO-rat compared to the Con-
trol-rat (rats infused with IgGAQP4+2 and IgGControl2, D7) using neurofilament immunostaining: reduced number of axons detected as NF-M-positive
spots in the white matter (WM); fragmentation and reduced axon thickness in the gray matter (GM). b Classification (10–20 to 100–140 μm2, ImageJ)
and quantification (mean by field) of NF-M-positive spots in the spinal cord of the NMO-rats (n = 6) compared to the Control-rats (n = 6): loss of axons
with 60–140 μm2 sections in the NMO-rats (in cart: evaluation of the total axon number, p = 0.03). c Co-detection of myelin alteration (MBP in green)
and axonal loss (neurofilament NF-M subtype in red) in the spinal cord of the NMO-rat compared to the Control-rat. d Increased expression of the
NF-H phosphorylated form, a marker of axon injury, detected by Western blot (pNF-H/NF-H ratio; p = 0.04). e Axon fragmentation and loss in
the optic nerve of the NMO-rats compared to the Control-rat detected by NF-M immunostaining. Scale bars = 20 μm
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cells—Fig. 8e). They were compared to rat infused with
the non-depleted IgGAQP4+ (NMO-rats, n = 3). AQP4 ex-
pression and myelin and axonal integrity were examined
at D7 in the spinal cord using the methods described
above. As expected, AQP4 expression decreased in the
NMO-rats whereas AQP4-IgG depletion partially pre-
vented such a decrease, as shown by immunodetection
(Fig. 8a) and signal quantification (Fig. 8d, NMO-
ratsAQP4+dep versus NMO-rats, p = 0.0001) In parallel,
IgGAQP4+dep induced less myelin disorganization and
MBP decrease (Fig. 8b, d) than IgGAQP4+ (p = 0.001) but
has less on effect on axonal loss (Fig. 8c, d). All these
observations confirmed the direct role of AQP4-IgG in
the lesions observed in our study model.
Assuming that IgG infusion in the CNS could induce im-
mune cell infiltration in the rat CNS, we looked for the
presence of CD8+, CD45RA+, and CD45+ cells and MPO+
(neutrophil) in the brain, spinal cord, and optic nerve of the
NMO-rats (n = 4) and the Control-rats (n = 4) (D7) by
using IHC. The immune cells were detected at the same
low level in the NMO-rats and the Control-rats (Additional
file 3: Figure S3, CD45+ cells as example). This indicated
that perfusion of IgG induced only a mild inflammation.
Accordingly, microglia did not display a detectable hall-
mark of activation or proliferation, as shown by examin-
ation of Iba1-positive cells (activated microglia) in the
spinal cord and optic nerve (not shown).
In our study model, we were not able, using IHC, to
detect perivascular complement deposition in any CNS
structure, including the spinal cord and optic nerve. To
check the possible role of innate complement activation
in lesion formation, we treated rats with cobra venom
prior to IgG brain infusion to abolish endogenous com-
plement activation [31]. NMO-like lesions occurred at
the same level in the treated or not treated NMO-rats
(not shown), demonstrating that complement does not
enhance injury in our model.
Globally, NMO-like lesion formation was mainly
dependent on the presence of AQP4-IgG but less, if not,
on other inflammatory factors.
Discussion
We herein propose a model, based on prolonged CSF in-




Fig. 7 Motor impairment in NMO-rat. Motor skills of the NMO-rats (red symbols, n = 10, rats infused with IgGAQP4+2) as compared to the Saline-rats
(white symbols, n = 10). a Rotarod experiment measuring the latency to fall from the rotating rod at D3, D7, D10, D14, and D21 after IgG infusion,
expressed as percent of D0 scores (latencies). The NMO-rats showed impairment in this task and fell much sooner from the rod than the Saline-rats.
b Walking experiment measuring deviation from the linear trajectory initially chosen by the rat at D7, D14, and D21, expressed as percent of D0 shifts
(*p < 0.05; **p < 0.01, ANOVA followed by post hoc tests). c Western blot analysis of the spinal cord of all rats at D21: altered expression of AQP4, GLT1,
and pNF-H in the NMO-rats compared to the Control-rats
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positive patients, that challenges the intrinsic effect of
the autoantibody in NMO physiopathology and ascertain
its clinical impact. We show that a prolonged CSF infu-
sion of IgGAQP4+ led to the diffusion of antibody in the
CNS, including the optic nerve and spinal cord. We
found that infused IgGAQP4+ has the ability to induce
astrocyte functional and morphological modification in
these structures. Astrocytopathy was associated to mye-
lin modification, to loss of oligodendrocyte and axon,
and to clinical motor impairment that could be partly
driven by glutamate homeostasis disruption. Our results
support that astrocytopathy, myelin and axonal damage
reported in NMO, is, to some extent, driven by intra-
thecal AQP4-IgG itself and in the absence of major
complement activation and immune cell infiltration and
confirm the role of CSF-AQP4-IgG.
It is now clear that AQP4-IgG are not only a surrogate
biomarker but play an important role in NMO patho-
physiology. In animal models, intraperitoneal injection
of AQP4-IgG in the context of T cell-mediated brain
inflammation or intracerebral co-injection of AQP4-IgG
and complement induced NMO-like lesions [16–18]. In
addition, incubation of the spinal cord slice cultures or pri-
mary astrocytes with AQP4-IgG required complement or
natural killer cells to demonstrate robust specific cell de-
struction [19, 20]. These in vitro and animal experiments
clearly demonstrated that AQP4-IgG induce astrocytic loss
through complement activation, T cell activation, and im-
mune cell cytotoxicity. We reported here that AQP4-IgG
per se can also induce astrocytopathy and downstream
NMO-like tissue lesions, independent of such neuro-
inflammatory processes. We thus showed that histological,
biochemical, and clinical changes can be mediated by in-
fused IgGAQP4+. Immunoglobulin effect per se was demon-
strated since our CNS infusion paradigm did not induce
major immune cell infiltration nor microglial cells activa-
tion, complement deposit was absent in tissue lesion and
complement inhibition by cobra venom did not decrease
astrocytopathy. Lack of major perivascular complement




Fig. 8 Lesions in the NMO-rat spinal cord depends on the presence of AQP4-Ab. a–c AQP4 expression and myelin (MBP) and axon (NF-M) integrity in
the spinal cord (IHC on axial and longitudinal slices, scale bars = 20 μm) of the NMO-rat, Control-rat, and rat perfused with purified IgG depleted in
IgGAQP4+: NMO-ratAQP4+dep (D7). d Quantification of fluorescence intensity and axon numeration showed that AQP4-Ab depletion reduced the lesion
extend in the spinal cord analyzed for AQP4 (***p < 0.001) and MBP (***p < 0.001). e Depletion reduced the amount of AQP4-Ab in IgGAQP4+dep by
40 %, as shown by flow cytometry analysis on HEK-AQP4 cells
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pathology studies reporting heterogeneous type of tissue
lesions in NMO [15, 32]. AQP4 antigen specificity was
demonstrated by the absence of the effect of the control
IgG and the dramatic decrease of the effect in AQP4-IgG-
depleted IgG. Our study thus validates a concept that has
been already suggested in NMO by several in vitro studies
[12–14, 24] and in animal models based on passive trans-
fer of AQP4-IgG in the periphery [33] or iterative injection
of AQP4-IgG directly into the spinal cord [21, 34]. There
are accumulative evidences for such intrinsic effect of auto-
antibody against surface antigens in other antibody-
mediated CNS disorders. This has been described recently
in an animal model of anti-NMDA-receptor-antibody en-
cephalitis based upon a common paradigm of CNS infu-
sion of purified IgG from CSF patients. Planaguma et al.
reported a specific targeting of the hippocampus by infused
IgG, leading to a downregulation of NMDA-receptor ex-
pression and several clinical changes mimicking human
disease, in the absence of additional neuro-inflammatory
processes [35]. By contrast to this emerging field of auto-
immune synaptopathies, characterized by autoantibody
permanently present in the CSF, AQP4-IgG is mainly
present in the blood [36, 37]. However, the presence of
AQP4-IgG in the blood is not sufficient to induce NMO
lesion. Indeed AQP4-IgG can be present for years in the
periphery without any symptoms [38], and the binding to
target antigen in the periphery rarely causes damage
[39, 40]. By contrast, AQP4-IgG- and AQP4-producing
cells have been identified in the CSF of NMO patients, es-
pecially during exacerbation [16, 41]. In established NMO
lesions, CNS tissues contain IgG-producing plasma cell.
Overall, if the exact role of intrathecally versus peripher-
ally produced AQP4-IgG is not yet clearly established,
there is increasing evidence for intrathecal production of
AQP4-IgG [42]. For all these reasons, we proposed a
NMO model that mimics the presence of AQP4-IgG in
the CNS fluid.
Intrathecal IgGAQP4+ in rat induces an astrocytopathy
that was characterized by a functional alteration rather
than an obvious astrocytic death. AQP4 loss, detected in
the spinal cord and optic nerve of the NMO-rats, was
more intense that demyelination, corroborating the obser-
vation that astrocytic alteration precede myelin injury in
NMO [6]. We propose a coordinated alteration of AQP4
and membrane-associated astrocytic proteins as key ele-
ments of NMO pathogenesis. In particular, we suspect glu-
tamate as a candidate for alterations in NMO because
glutamate transporters GLT1/EAAT2 and GLAST/EAAT1
coexist extensively with AQP4 at astrocyte membrane, and
a functional link between AQP4 and GLT1 has been re-
ported [43]; AQP4 and GLT1 are downregulated in CNS le-
sions of NMO patients [13]; and finally, contact with
AQP4-IgG leads to GLT1 endocytosis [8, 13] and maintains
its sequestration into the cytoplasmic compartment (our
data herein). Alteration of glutamate transporters activity
could thus result in defective glutamate clearance, an im-
portant function preventing glutamate-induced toxicity.
We previously shown that chronic contact of the antibody
with cultured astrocytes altered glutamate homeostasis
(glutamine synthase activity decreased, glutamate release
increased) and subsequently damaged oligodendrocytes
[24]. In the NMO-rat, we observed a defective glutamate
uptake in the rats chronically infused with AQP4-IgG. This
metabolic defect was associated with oligodendrocyte loss.
A link between altered glutamate homeostasis, myelin
defect, and motor deficit may therefore exist in NMO. Glu-
tamate excitotoxicity, secondary to AQP4-IgG-induced
alteration in astrocytes, is plausible because glutamate re-
ceptors family are present in oligodendrocytes and distrib-
uted in myelinated fibers and because astrocytes have the
ability to release glutamate and subsequently activate
NMDA-receptor, notably in spinal cord, inhibiting or po-
tentiating synaptic activity [44–46]. Astrocytes release glu-
tamate through distinct molecular mechanisms, including
vesicular exocytosis and functional hemichannels [47, 48].
In fact, connexin hemichannels, which directly connect the
cell cytoplasm to the extracellular space, act as release site
for transmitters like glutamate and play a pivotal role in
neuron-glial cell crosstalk [49]. In particular, in myelin
sheath, connexin-mediated glia networking participates in
gliotransmission and impacts myelination and remyelina-
tion [50]. Interestingly, a correlation of connexin expression
with myelin loss and astrogliosis has been recently reported
in NMO lesions [51].
Conclusions
Our study demonstrates that AQP4-IgG infused in the
CSF is, per se, pathogenic in NMO. Our experiments
show that some NMO lesions are initiated by AQP4-IgG
binding to its target, in the absence of further comple-
ment activation, immune cell infiltration, and astrocytic
death. The demyelination and axonal loss can be sec-
ondary to astrocytopathy, partly driven by glutamate
excitotoxicity. We therefore suggest that treatment pro-
tecting astrocyte, including dimethyl fumarate [52] or
laquinimod [53], could be of major interest in NMO.
Our rat NMO model should also be useful for evaluating
novel treatments targeting pathogenic autoantibodies, as
intravenous IgG, and enzyme targeting and specifically
inactivating human IgG antibodies.
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Animal experiments were carried out in strict accordance
with the European Directive 2010/63/UE and follows the
ARRIVE guidelines on the protection of animals used for
scientific purposes. Adult male OFA rats at 280 g (Janvier;
Le Genest Saint Isle, France) were acclimated to the new
environment for 7 days prior to the start of the experiment.
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Relevant raw data are freely available.
Additional files
Additional file 1: Figure S1. Characterization of IgGAQP4+ used for rat
brain infusion. A IgGAQP4+ binding (green) on spinal cord and optic nerve
from naïve rat (longitudinal sections, immunofluorescence, IgGAQP4+ 2 as
example): co-localization with GFAP (red) and AQP4 (red) on astrocyte
processes. Scale bar = 20 μm. B, C Reduction of AQP4 in total cell lysate
(B) and membrane preparation (C) of cultured astrocytes following 24 h
contact with IgGAQP4+; IgGControl had no similar effect (Western blot, actin
as control for protein deposition).
Additional file 2: Figure S2. Stepping sequence analysis. A Weight
curves of NMO-rats and Control-rats during motor behavior analyses.
B Deviation from the linear trajectory initially chosen by the rat once it
entered the corridor was computed and scored, using the left forepaw
prints.
Additional file 3: Figure S3. Low immune cell infiltration in NMO-rat.
CD45+ lymphocytes infiltrated in the brain, optic nerve, and spinal cord
of NMO-rat and Control-rat at low level (D7). Scale bar = 20 μm.
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